Please find attached the notice for the Extraordinary General Meeting (EGM) of EXACT Therapeutics to be held on 24 July 2020 at 15:00 (CET).
Due to coronavirus, shareholders are encouraged to grant the Chair of the Board an authorisation with or without voting instructions.
The notice for the EGM includes the Board’s proposed resolutions, notice of attendance and proxy forms. The notice is also available on the website of EXACT Therapeutics.
For further queries, please contact:
Masha Stromme, Chair +47 93022509
Stig Jarle Pettersen, CFO +47 90960336
EXACT-Tx is a clinical stage Anglo-Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com